The Laryngoscope · 2015
Onabotulinum toxin A dosage trends over time for adductor spasmodic dysphonia: A 15-year experience.
Оценочное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tang Christopher G, Novakovic Daniel, Mor Niv, Blitzer Andrew
Аннотация
OBJECTIVES/HYPOTHESIS: Although onabotulinum neurotoxin A (BoNTA) has been used for over three decades for the treatment of adductor spasmodic dysphonia, no study has been performed to look at the trend of BoNTA dosages across time. The goal of this study is to evaluate the dosage trends to determine if the dosage necessary for voice improvement in patients increases over time.
STUDY DESIGN: Charts were reviewed for patients with 15 years or more of experience.
METHODS: Linear regression analysis was performed to determine correlation coefficients and trends.
RESULTS: Fifty-five patients receiving BoNTA injections by the senior author (a.b.) for over 15 years were evaluated. Thirty-nine patients (82% female) met inclusion criteria. Patients received injections over an average of 18.6 years ± 1.36 years, with the longest follow-up of 21.5 years. Of 39 patients, 16 (41%) had a negative correlation coefficient (Pearson's r) suggesting a decrease over time, whereas 23 (59%) had a positive correlation coefficient suggesting an increase over time. The mean correlation coefficient was 0.139 ± 0.534 and P < 0.05 in 19 patients and P > 0.05 in 20 patients. R(2) for all patients were less than 0.75.
CONCLUSIONS: Onabotulinum neurotoxin A injection dosage trends vary depending on the individual over time. Overall, the dose range appears to be stable in the majority of patients, suggesting that tolerance does not play a significant part in dose variation over time.
LEVEL OF EVIDENCE: 4. Laryngoscope, 126:678-681, 2016.
STUDY DESIGN: Charts were reviewed for patients with 15 years or more of experience.
METHODS: Linear regression analysis was performed to determine correlation coefficients and trends.
RESULTS: Fifty-five patients receiving BoNTA injections by the senior author (a.b.) for over 15 years were evaluated. Thirty-nine patients (82% female) met inclusion criteria. Patients received injections over an average of 18.6 years ± 1.36 years, with the longest follow-up of 21.5 years. Of 39 patients, 16 (41%) had a negative correlation coefficient (Pearson's r) suggesting a decrease over time, whereas 23 (59%) had a positive correlation coefficient suggesting an increase over time. The mean correlation coefficient was 0.139 ± 0.534 and P < 0.05 in 19 patients and P > 0.05 in 20 patients. R(2) for all patients were less than 0.75.
CONCLUSIONS: Onabotulinum neurotoxin A injection dosage trends vary depending on the individual over time. Overall, the dose range appears to be stable in the majority of patients, suggesting that tolerance does not play a significant part in dose variation over time.
LEVEL OF EVIDENCE: 4. Laryngoscope, 126:678-681, 2016.
Предметные рубрики MeSH
AdultBotulinum Toxins, Type ACohort StudiesDose-Response Relationship, DrugDrug Administration ScheduleDysphoniaFemaleFollow-Up StudiesHumansInjections, IntralesionalMaleMiddle AgedNeuromuscular AgentsRetrospective StudiesRisk AssessmentSeverity of Illness IndexTime FactorsTreatment OutcomeVoice QualityYoung Adult